Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$95.50 USD

95.50
1,324,649

+1.07 (1.13%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $95.51 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals

by Zacks Equity Research

AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.

Zacks Equity Research

Here's Why You Should Hold Allscripts Stock in Your Portfolio

by Zacks Equity Research

Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.

Nitish Marwah headshot

New Strong Buy Stocks for December 14th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ILMN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

BD Gets Enterprise Level Cybersecurity Assessment From UL

by Zacks Equity Research

BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.

Zacks Equity Research

Here's Why Investors Should Hold Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

Zacks Equity Research

Illumina (ILMN) Takes Part in NIH Program With Genotype Launch

by Zacks Equity Research

The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.

Zacks Equity Research

Ecolab to Boost Food Safety Standards With Holchem Buyout

by Zacks Equity Research

Ecolab (ECL) to benefit from Holchem Group's unique offerings for the food and beverage, foodservice and hospitality industries.

Zacks Equity Research

Here's Why Investors Should Hold AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.

Zacks Equity Research

Cooper Companies (COO) Earnings Miss & Revenues Beat in Q4

by Zacks Equity Research

Cooper Companies (COO) gains from solid segmental performance in fiscal Q4.

Zacks Equity Research

Patterson Companies (PDCO) Q2 Earnings Beat, Revenues Miss

by Zacks Equity Research

Patterson Companies (PDCO) continues to gain from its Animal Health unit in fiscal Q2.

Zacks Equity Research

Veeva Systems Announces New DAM Solution for Life Sciences

by Zacks Equity Research

Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.

Zacks Equity Research

Here's Why You Should Hold Pacific Biosciences (PACB) Now

by Zacks Equity Research

Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.

Zacks Equity Research

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

HealthEquity's (HQY) impressive results in Q3 can be attributed to solid growth in HSA Members. Its bullish guidance for fiscal 2019 further raises investors' optimism on the stock.

Zacks Equity Research

Illumina, Douglas Dynamics, Amazon, JPMorgan and Apple highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Illumina, Douglas Dynamics, Amazon, JPMorgan and Apple highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Illumina (ILMN)

by Kevin Cook

This NASA of Biotechnology provides power-tools and starships for exploring the human genome

Zacks Equity Research

Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Illumina (ILMN) closed the most recent trading day at $337.50, moving -0.14% from the previous trading session.

Zacks Equity Research

Veeva Systems (VEEV) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems' (VEEV) impressive Q3 results can be attributed to the Subscription Service segment's solid performance. An upbeat FY19 guidance instills investor optimism in the stock

Panel Of Zacks Experts headshot

Top Stock Picks for the Week of November 26th

by Panel Of Zacks Experts

A Biotech and Software Company Round Out November Picks

Zacks Equity Research

PerkinElmer's Vanadis NIPT CE Mark Boosts Prenatal Prospects

by Zacks Equity Research

PerkinElmer's (PKI) Vanadis NIPT is a more cost effective and non-invasive screening system compared to traditional ones.

Zacks Equity Research

Medtronic's Deal With Nutrino Health to Boost Diabetes Arm

by Zacks Equity Research

Bringing Nutrino under Medtronic's (MDT) Diabetes Group will help the acquirer speed up its growth in the same business.

Zacks Equity Research

Medtronic Gets Health Canada License for Visualase System

by Zacks Equity Research

Medtronic (MDT) adopts initiatives to boost top-line contributions from the Brain Therapies arm.

Zacks Equity Research

Zacks.com highlights: Crocs, Illumina, Twitter, Vocera Communications and Cardtronics

by Zacks Equity Research

Zacks.com highlights: Crocs, Illumina, Twitter, Vocera Communications and Cardtronics

Zacks Equity Research

Illumina (ILMN) Up 7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.